Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
NCT ID: NCT01783340
Last Updated: 2014-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1/PHASE2
INTERVENTIONAL
2013-04-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CQ and falciparum immunization
This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Placebo capsules daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given.
Placebo
Placebo capsules will be administered at each immunization
Immunization with falciparum
three inoculations with 5 infected mosquito bites
CQ/AZM and falciparum immunization
This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).
Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given.
Azithromycin capsules
Azithromycin capsules will be administered at each immunization
Immunization with falciparum
three inoculations with 5 infected mosquito bites
CQ and AZM control
This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.
Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.
Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given.
Azithromycin capsules
Azithromycin capsules will be administered at each immunization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azithromycin capsules
Azithromycin capsules will be administered at each immunization
Placebo
Placebo capsules will be administered at each immunization
Immunization with falciparum
three inoculations with 5 infected mosquito bites
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Good health based on history and clinical examination
3. Negative pregnancy serum test
4. For females who are sexually active: use of adequate contraception (incl. condom use)
5. Signing of the informed consent form, thereby demonstrating understanding of the meaning and procedures of the study
6. Agreement to inform the general practitioner and to sign a request to release medical information concerning contra-indications for participation in the study
7. Willingness to undergo a Pf controlled infection through mosquito bites
8. Agreement to stay in a hotel room close to the trial centre during a part of the study (Day 7 till day 15 after challenge)
9. Reachable (24/7) by mobile phone during the whole study period
10. Available to attend all study visits
11. Agreement to refrain from blood donation or for other purposes, during the whole study period
12. Willingness to undergo HIV, hepatitis B and hepatitis C tests
13. Negative urine toxicology screening test at screening visit and the day before challenge
14. Willingness to take a prophylactic regime of chloroquine or chloroquine/azithromycin combination and a curative regimen of Malarone® after challenge.
Exclusion Criteria
2. Plans to travel to malaria endemic areas during the study period
3. Plans to travel outside of the Netherlands during the challenge period
4. History of stay in malaria endemic areas for more than 6 months
5. Previous participation in any malaria vaccine study and/or positive serology for Pf
6. Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteer
7. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
8. History of arrhythmias or prolonged QT-interval
9. Positive family history in 1st and 2nd degree relatives for cardiac events \< 50 years old
10. An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
11. Clinically significant abnormalities in electrocardiogram (ECG) at screening
12. Body Mass Index (BMI) below 18 or above 30 kg/m2
13. Any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
14. Positive HIV, HBV or HCV tests
15. Participation in any other clinical study within 30 days prior to the onset of the study
16. Enrolment in any other clinical study during the study period
17. Pregnancy or lactation for women
18. Volunteers unable to give written informed consent
19. Volunteers unable to be closely followed for social, geographic or psychological reasons
20. History of (soft) drugs or alcohol abuse interfering with normal social function
21. A history of treatment for psychiatric disease
22. A history of epileptic insults in the volunteer
23. Contra-indications for use of Malarone®, chloroquine or azithromycin. This includes hypersensitivity or treatment taken by the volunteer that interferes with mentioned study drugs.
24. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (topical corticosteroids and oral anti-histaminic are allowed) and during the study period
25. Any confirmed or suspected immunosuppressive or immunodeficient condition, including (functional) asplenia
26. Co-workers or trainees of the departments of Medical Microbiology, Parasitology, or Internal Medicine of the Leiden University Medical Centre
27. A history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia trait or G6PD deficiency
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Leiden University Medical Center
OTHER
Medicines for Malaria Venture
OTHER
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
RW Sauerwein, MD PhD
Role: STUDY_DIRECTOR
Radboud University Medical Center
LG Visser, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Leiden University Medical Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leiden University Medical Centre
Leiden, Leiden, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL42517.000.12
Identifier Type: OTHER
Identifier Source: secondary_id
MMV
Identifier Type: -
Identifier Source: org_study_id